We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Microfluidic Point-of-Care Diagnostics Now a Must-Have

By LabMedica International staff writers
Posted on 27 May 2014
Yole Développement (Lyon, France) released its new, in-depth market research report – “Point of Care Testing 2014: Applications for Microfluidic Technologies.”

“Diagnostic companies confirm the adoption of microfluidic technologies for point-of-care testing”, said Dr. Benjamin Roussel, Activity Leader, Medical Technologies, Yole Développement. Indeed the point-of-care(POC) market’s contribution to in vitro diagnostic is poised to increase from 13% to 17% over the next 5 years, leading to a market of around USD 30 billion in 2019. Under this context, the French consulting company Yole Développement released its report. Based on a complete analysis of the last 3 years’ developments, the company has been able to draw effective conclusions.

Image: Microfluidic-device market per point-of-care applications, from 2012 forecasted to 2019 (Photo courtesy of Yole Développement).
Image: Microfluidic-device market per point-of-care applications, from 2012 forecasted to 2019 (Photo courtesy of Yole Développement).

This technology and market study provides an in-depth analysis of microfluidic devices dedicated to POC; including nearly 60 new technologies, commercialized or close to market. Yole Développement’s report also proposes an innovative market segmentation combined with market forecasts. The analysis includes the following applications: emergency testing, home tests, doctor’s office screening, decentralized hospital tests, environmental testing, forensic and military, third-world infections, and agro-food applications.

“Different types of point of care tests are available on the market. Whereas simple lateral flow tests work perfectly without fluid management technology, microfluidics is necessary when test complexity increases,” said Dr. Roussel. Indeed, microfluidics is an enabling technology allowing miniaturization and integration of laboratory protocols into portable devices. Access to microfluidic technologies for diagnostic companies often passes through acquisitions, as this reduces the technology development risk and increases reactivity. The most recent acquisition was that of IQuum by Roche for USD 275 million in April 2014. In its new report, Yole Développement describes how mergers and acquisitions will decrease in volume but increase in value.

Microfluidic-based POC testing is expected to grow sharply, from USD 1.6 billion in 2013 to USD 5.6 billion in 2019, at a compound annual growth rate (CAGR) 2014–2019 of 23%. Diagnostics companies have realized the potential and several successful microfluidic POC products have been launched in the past few years.

Related Links:

Yole Développement



Gold Member
Veterinary Hematology Analyzer
Exigo H400
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Silver Member
Quality Control Material
NATtrol Chlamydia trachomatis Positive Control
New
Modular Hemostasis Automation Solution
CN Track

Latest Industry News

Quanterix Completes Acquisition of Akoya Biosciences
27 May 2014  |   Industry

Lunit and Microsoft Collaborate to Advance AI-Driven Cancer Diagnosis
27 May 2014  |   Industry

AMP Releases Best Practice Recommendations to Guide Clinical Laboratories Offering HRD Testing
27 May 2014  |   Industry



PURITAN MEDICAL